The effects of autoantibodies against the second extracellular loop of α1-adrenoceptor on vasoconstriction

Basic Research in Cardiology

Volumn 104, Issue 5, 2009, Pages 581-589

  Yan, Li ^a   Xu, Yanwu ^b   Yao, Hong ^a   Xue, Wenxin ^a   Tian, Jue ^a   Ren, Haiqiang ^c   Wu, Ye ^a   Yang, Guangzhao ^a   Ma, Xin L ^d   Liu, Huirong ^a,e  

^a SHANXI MEDICAL UNIVERSITY   (China)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c Department of Intensive Care Unit   (China)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Adrenergic; Alpha 1; Autoantibody; Hypertension; Receptor; Vasoconstriction

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1 ADRENOCEPTOR AUTOANTIBODY; AUTOANTIBODY; CELL RECEPTOR; IMMUNOGLOBULIN G; PRAZOSIN; UNCLASSIFIED DRUG;

ADULT; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY ISOLATION; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERTENSION; IN VIVO STUDY; ISOLATED ARTERY; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MESENTERIC ARTERY; MIDDLE CEREBRAL ARTERY; NONHUMAN; PATHOGENESIS; PROTEIN PURIFICATION; RAT; RENAL ARTERY; THORACIC AORTA; VASCULAR RESISTANCE; VASOCONSTRICTION;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; AGED; ANIMALS; AUTOANTIBODIES; BLOOD PRESSURE; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PRAZOSIN; PROTEIN STRUCTURE, TERTIARY; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC, ALPHA-1; TIME FACTORS; UP-REGULATION; VASCULAR RESISTANCE; VASOCONSTRICTION;

EID: 70349696242     PISSN: 03008428     EISSN: 14351803     Source Type: Journal    
DOI: 10.1007/s00395-009-0020-8     Document Type: Article

References (29)

1. 2+ via L-type calcium channels in heart cells by the autoantibody directed against the second extracellular loop of the alpha1-adrenoceptors. Can J Physiol Pharmacol 81:234-246
2. Bramos D, Ikonomidis I, Tsirikos N, Kottis G, Kostopoulou V, Pamboucas C, Papadopoulou E, Venetsanou K, Giatrakos N, Yang GZ, Nihoyannopoulos P, Toumanidis S (2008) The association of coronary flow changes and inflammatory indices to ischaemia-reperfusion microvascular damage and left ventricular remodelling. Basic Res Cardiol 103:345-355
3. Bøkenes J, Aronsen JM, Birkeland JA, Henriksen UL, Louch WE, Sjaastad I, Sejersted OM (2008) Slow contractions characterize failing rat hearts. Basic Res Cardiol 103:328-344
4. Dzielak DJ (1992) The immune system and hypertension. Hypertension 19:I36-I44
5. Eng H, Magnusson Y, Matell G, Lefvert AK, Saponja R, Hoeveke J (1992) Beta 2-adrenergic receptor antibodies in myasthenia gravis. J Autoimmunity 5:213-227
6. Fu ML (1995) Do immune system changes have a role in hypertension? J Hypertens 13:1259-1265
7. Fu ML, Herlitz H, Wallukat G, Hilme E, Hedner T, Hoebeke J, Hjalmarson A (1994) Functional autoimmune epitope on alpha 1-adrenergic receptors in patients with malignant hypertension. Lancet 344:1660-1663
8. Fu ML, Schulze W, Wolf WP, Hjalmarson A, Hoebeke J (1994) Immunocytochemical location of M2 muscarinic receptor in rat ventricles with anti-peptide antibodies. J Histochem Cytochem 42:337-343
9. 1-adrenergic receptor. Clin Exp Immunol 97:146-151
10. Subcommittee Guidelines (1999) 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. J Hypertension 17:151-183
11. Guimaraes S, Moura D (2001) Vascular adrenoceptors: An update. Pharmacol Rev 53:319-356
12. Keil U (2000) Coronary artery disease: The role of lipids, hypertension and smoking. Basic Res Cardiol 95(Suppl 1):I52-I58
13. Khraibi AA (1994) Immunoregulatory failure in the pathophysiology of hypertension. News Physiol Sci 9:27-30
14. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J (1996) Blood pressure and end-stage renal disease in men. N Engl J Med 334:13-18
15. Lazzerini PE, Capecchi PL, Guideri F, Acampa M, Selvi E, Bisogno S, Galeazzi M, Laghi-Pasini F (2008) Autoantibody-mediated cardiac arrhythmias: Mechanisms and clinical implications. Basic Res Cardiol 103:1-11
16. Li QX, Xiong ZY, Hu BP, Tian ZJ, Zhang HF, Gou WY, Wang HC, Gao F, Zhang QJ (2008) Aging-associated insulin resistance predisposes to hypertension and its reversal by exercise: The role of vascular vasorelaxation to insulin. Basic Res Cardiol [Epub ahead of print]
17. Liao YH, Wei YM, Wang M, Wang ZH, Yuan HT, Cheng LX (2002) Autoantibodies against AT1-receptor and alpha1-adrenergic receptor in patients with hypertension. Hypertens Res 25:641-646
18. 2 -muscarinic acetylcholine receptors in 408 healthy subjects of varying ages. Autoimmunity 29:43-51
19. Luther HP, Homuth V, Wallukat G (1997) Alpha 1-adrenergic receptor antibodies in patients with primary hypertension. Hypertension 29:678-682
20. Magnusson Y, Marullo S, Hoyer S, Waagsrein F, Andersson B, Vahlne A, Guillet JG, Strosberg AD, Hjalmarson A, Hoebeke J (1990) Mapping of functional autoimmune epitope on the beta 1-adrenergic receptor in patients with idiopathic dilated cardiomyopathy. J Clin Invest 86:1658-1663
21. Makaritsis KP, Gavras H, Du Y, Chobanian AV, Brecher P (1998) Alpha1-adrenergic plus angiotensin receptor blockade reduces atherosclerosis in apolipoprotein E-deficient mice. Hypertension 32:1044-1048
22. Matsui S, Fu ML (1998) Myocardial injury due to G-protein coupled receptor-autoimmunity. Jpn Heart J 39:261-274
23. Messerli FH, Williams B, Ritz E (2007) Essential hypertension. Lancet 370:591-603
24. Singh RB, Suh IL, Singh VP, Chaithiraphan S, Laothavorn P, Sy RG, Babilonia NA, Rahman AR, Sheikh S, Tomlinson B, Sarraf-Zadigan N (2000) Hypertension and stroke in Asia: Prevalence, control and strategies in developing countries for prevention. J Hum Hypertens 14:749-763
25. Stamler J, Stamler R, Neaton JD (1993) Blood pressure, systolic and diastolic, and cardiovascular risks: US population data. Arch Intern Med 153:598-615
26. 1-adrenergic receptor autoantibodies in refractory hypertension. PLoS ONE 3:e3742
27. Whitworth JA, World Health Organization International Society of Hypertension Writing Group (2003) 2003 World Health Organization (WHO)/ International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 21:1983-1992
28. Yusuf S, Reddy S, Ounpuu S, Anand S (2001) Global burden of cardiovascular diseases. Part α: General considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 10:76-80
29. 1-adrenergic receptor on the proliferation of vascular smooth muscle cells in rats. Chin J Pathophysiol 22:274-278